Stockscreener 앱 받기
0.00
2.62%
17.97
시간 외 거래:
19.90
19.90
+
Defiance Trillion Dollar Club Index Etf 주식(TRIL)의 최신 뉴스
PA Daily | Coinbase CEO denies White House will withdraw support for the CLARITY Act; Bitcoin spot ETF sees net inflows of $1.42 billion this week. - 富途牛牛
Defiance ETFs Announces Closure of Select Funds - The Manila Times
Defiance Trillion Dollar Club Index ETF (TRIL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ETF Prime: Murphy on the New Faces of the ETF Boom - ETF Database
ETF Trades: What Has and Hasn’t Worked in 2025ETF Prime with Nate GeraciPodcasts - Advisor Perspectives
TRIL ETF Holdings List — BOATS:TRIL - TradingView
Defiance floats ETF tied to firms, digital assets valued above US$1 trillion - Structured Retail Products
TRIL Stock Fund Price and Chart — BOATS:TRIL - TradingView — Track All Markets
US ETF launches from 25th September to 2nd October, 2025 - ETF Express
‘$1 Trillion Club’ ETF Offers Investors Exposure to Tech Giants and Bitcoin - The Currency analytics
Defiance Trillion Dollar Club Index ETF (NASDAQ: TRIL)Share Price - intelligentinvestor.com.au
A new "Trillion Dollar" ETF based on stocks and Bitcoin has appeared in the US. - Happy Coin News
'$1T Club' ETF offers exposure to tech giants and Bitcoin - Bitget
Tron Inc. Shares Tumble 85% From June Peak Amid DAT Market Slump - Decrypt
Defiance ETFs Launches New Trillion-Dollar Assets ETF: U.S. Access to Tech Giants and Crypto-Linked Plays - Blockchain News
SEC No-Action Letter Creates Opening for More Firms to Serve as Crypto Custodians - Decrypt
Ripple CTO David Schwartz to Step Back, Remain on Board as CTO Emeritus - Decrypt
'$1 Trillion Club' ETF Gives Investors Exposure to Tech Giants—And Bitcoin - Decrypt
Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New “Magnificent 7” of Global Markets - GlobeNewswire
TRIL ETF Analysis: Dividends, Returns NASDAQ:TRIL - TradingView — Track All Markets
Defiance Launches JEDI – Drone & Modern Warfare ETF: Exposure to Leading Drone and Modern Warfare Companies - GlobeNewswire
Defiance ETFs Launches QLDY, the First ETF to Pay Distributions Twice Weekly * - GlobeNewswire
Defiance’s QTUM – Quantum Computing ETFSurpasses $2 - GlobeNewswire
Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Sec - Barchart.com
Defiance ETFs Launches Leveraged + Income ETFs for AMD (AMDU) and Super Micro Computer (SMCC) - GlobeNewswire
Defiance ETFs Launches Leveraged + Income ETFs for Palantir - GlobeNewswire
Defiance Launches VIXI: Enhanced Long Volatility ETF with Leveraged Short S&P 500 Exposure - GlobeNewswire
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure - GlobeNewswire
Weekly ETF Industry Recap: U.S., Europe, and Canada Highlights – July 7-July 11, 2025 - Trackinsight
Pfizer ends Phase 1b/2 trial for final Trillium CD47 drug - Endpoints News
Defiance ETFs Unveils $MST: The First Leveraged MicroStrategy ETF that Seeks to Pay Income Weekly - GlobeNewswire
Defiance Launches $GLDY, Gold Enhanced Options Income ETF - GlobeNewswire
Defiance’s XMAG ETF Outshines S&P 500 Amid “Magnificent 7” - GlobeNewswire
Defiance ETFs' QTUM, Quantum Computing ETF, Earns 5-Star Morningstar Rating and Surpasses $1 Billion in AUM - GlobeNewswire
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - GlobeNewswire
$QTUM, Defiance Quantum Computing ETF, Surpasses $1 Billion in AUM - GlobeNewswire
Defiance Launches XMAG The First ETF Offering Exposure to the S&P 500 Excluding the “Magnificent 7” Tech Giants - GlobeNewswire
Defiance ETFs Announces Monthly Distributions on $QQQY - GlobeNewswire
GlobeNewswire by Notified - The Manila Times
Quell Therapeutics Appoints Experienced Biopharma Leader - GlobeNewswire
Genexine, EPD Biotherapeutics to merge for new protein degraders - BioWorld MedTech
Pension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest funds - The Globe and Mail
Pfizer to acquire Trillium in $2.3bn deal - BioProcess International
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment - PR Newswire
Ozempic maker Novo Nordisk bulks up on weight loss drugs, buying Montreal’s Inversago for $1-billion - The Globe and Mail
Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month - The Globe and Mail
Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs - The Globe and Mail
GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family - The Globe and Mail
Jan Skvarka, former Trillium CEO, on Driving a Turnaround - Timmerman Report
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors - citybiz
Autobahn Therapeutics raises funds to advance ABX-002 for treatment-resistant depression - BioWorld MedTech
Doxorubicin Market Revenue to Cross $1,983.40 million by - GlobeNewswire
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors - Quantisnow
Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers - PR Newswire
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswire
Shifting from megamergers to strategic collaboration: M&A predictions for biopharma - European Pharmaceutical Review
The top 10 biopharma M&A deals in 2021 - Fierce Pharma
TCR² Therapeutics Appoints Rosemary Harrison as Chief Business and Strategy Officer - citybiz
Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal - Reuters
Pfizer acquires immuno-oncology firm Trillium for $2.22bn - Pharmaceutical Technology
Pfizer Acquires Trillium Therapeutics - citybiz
Xenon Pharmaceuticals shares soar on strong results for epilepsy drug - The Globe and Mail
UPDATE: Pfizer and Trillium: How a $25M investment led to a $2.3B buyout - Fierce Biotech
Determining the Outcomes of TTI-622 With Azacitidine for TP53-Mutant AML - Targeted Oncology
1.23%
자본화:
|
볼륨(24시간):